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Rituximab, a chimeric CD20 monoclonal antibody that causes
depletion of B cells, shows short-term treatment efﬁcacy in 40% to
60% of immune thrombocytopenia (ITP) patients.1,2 Our recently
published multicenter randomized open-label phase 2 trial comparing
3 rituximab dosing schemes showed 50% responses in 138 ITP pa-
tients.3 Unfortunately, the treatment efﬁcacy of rituximab so far cannot
be predicted. Here, however, we show absent levels of platelet-bound
antibodies to be associated with refractoriness to rituximab. Assays
on platelet-bound antibodies may hence lead to a more personalized
treatment approach for these patients.
ITP was diagnosed in accordance with the recommendation of the
AmericanSocietyofHematology (ASH),4 bypatient and familyhistory,
physical examination, and laboratory investigations (eg, normal white
blood cell count and differentiation, normal red blood cell count, red
blood cell indices andmeanplatelet volume, absenceofHIV,hepatitisB
virus, hepatitis C virus, Helicobacter pylori, and antinuclear factor,
antinuclear antibody, antiphospholipid antibodies). Furthermore, low to
normal thrombopoietin levels supported thrombocytopenia to be due to
increased platelet destruction.5 Eligible patients were 18 years of age or
older, with an ITP relapse or refractoriness (minimally 2 platelet counts
,30 3 109/L), at least 3 weeks after high-dose ($1 mg/kg) cor-
ticosteroids, who were randomized between 3 rituximab dosing
schemes, that is, 2 or 4 once-weekly standard 375 mg/m2 doses and a
twice-weekly 750mg/m2 regimen.3 Complete response (CR), good/
partial response (PR), and moderate response (MR) were deﬁned
as platelet counts of 1503 109/L or more, 503 109/L or more on 2
consecutive occasions, and a platelet count over 30 3 109/L with at
least twice the baseline count, respectively. The different dosages of
rituximab did not lead to changes in response rate.3
Prior to starting the ﬁrst rituximab dose and subsequently for
10 weeks, weekly EDTA-anticoagulated blood sampling was
requested to assess the presence of platelet-associated immuno-
globulin G (IgG) and IgM autoantibodies by the direct platelet
immunoﬂuorescence test (PIFT) and the eluate-(indirect) PIFT, as
described previously.6 In the current report, a positive “PIFT”
refers to the combination of a reactive (5 11 to 31) direct as well
as eluate PIFT. One or both tests with negative reactions were
deﬁned as a negative “PIFT.” Additionally, in samples with
sufﬁcient platelet numbers, both the PIFT and a direct monoclonal
antibody immobilization of platelet antigens (MAIPA) assay were
performed; the latter todetect IgG-class autoantibodies.7Allmonoclonal
antibodies, CLBthromb/1 (CD41, anti-glycoprotein IIb [GPIIb]),MB45
(CD42a, anti-GPIX), and SW16 (CD42d, anti-GPV) were supplied by
Sanquin Reagents (Amsterdam, The Netherlands).
For statistical analysis, correlation between continuous variables
was calculated by the Spearman rank test, association between
categorical valuables was calculated by the 2-tailed Fisher exact prob-
ability test, and 95% conﬁdence intervals (CIs) were calculated using
Stata version 14.0 (StataCorp LP).
Prerituximab treatment samples from 112 of 138 patients and
follow-up samples during and after rituximab treatment from 80
patients were sent to our laboratory (supplemental Figure 1, available
on the BloodWeb site).
In 99 of 112 patient samples (88%), the platelet count in
prerituximab treatment samples was sufﬁcient to enable
platelet-associated autoantibody detection by PIFT. Of these, a
representative 47 (47%) responded to rituximab (CR, n5 17; PR,
n 5 22; and MR, n 5 8, respectively) whereas 52 (53%) were
nonresponders (NRs). For all tested patients (n 5 99), direct
PIFT results corresponded with the eluate-PIFT results. Antibodies
were present in 79 patients, of whom 43 responded (54%) with 16
complete (21%). In contrast, the absence of antibodies in 20 patients
was associated with 4 responses (20%) of which only 1 (5%) was
complete (Table 1; P 5 .006). In summary, undetectable platelet
autoantibodies in the direct PIFT strongly predict absence of or less
than complete response to rituximab (Table 1; negative predictive
value, 95.0%; CI, 73.2%-99.25%, positive predictive value, 20.3%;
CI, 17.7%-23.1%).
Vice versa, 16 patients (94%) with a complete response to
rituximab showed positive to very-strong-positive direct PIFT
reactions (mean level, 21) whereas the percentage of non-
responsive patients with a positive direct PIFT was much lower
(69%; P 5 .051). In patients with partial or moderate platelet
responses, positive PIFT occurred with similar frequency in 19
(86%) and 8 (100%), respectively.
Serial autoantibody testing was performed for 80 of the
sampled patients (71%). Of these, the presence of platelet
autoantibodies and corresponding platelet counts were evaluated
“per response group” at baseline and at the time of the highest
platelet counts that were reached within 10 weeks after start of
rituximab treatment (Figure 1; supplemental Figure 2). Of 30
patients predominantly responding (10 CR, 10 PR, 3 MR), the
platelet count also enabled the direct MAIPA. Both PIFT and
MAIPA results in these patients appeared in full concordance, that
is, 7 patients (4 NR and 3 PR) were negative with both PIFT and
directMAIPA and 23 (3 NR, 3MR, 7 PR, and 10 CR) positive with
both PIFT and direct MAIPA.
CR in the Haemato Oncology Foundation for Adults in The
Netherlands (HOVON) 64Studywas deﬁned as a rise in platelet counts
to 150 3 109/L or more. Nowadays, ITP is deﬁned as platelet
counts ,100 3 109/L.8 Recategorization of the response groups,
using 100 3 109/L did not result in different response numbers.
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Anti-CD20 monoclonal antibodies deplete B cells for periods
varying frommonths to.1 year. In this respect, B cells are essential to
present antigens to CD41 T cells and moreover secrete cytokines-
activating macrophages, dendritic cells, and immune-regulatory cells
and thus an ongoing autoimmune response.9-11Additionally, rituximab
is reported to normalize both the abnormalities and dysfunction of
the T-cell compartment in ITP patients.9,12-14 However, depletion of
pre–plasma cell B cells, andwith it decreased autoantibody production,
is regarded as the most likely mechanism of action. But, so far not one
of these explanations could be correlated to rituximab’s variable
therapeutic effects.
Our results are in agreement with the latter mechanism, whereas
all serially tested CR patients (n 5 16) showed decreasing antibody
results and32of 39nonresponsive patients havenondecreasing autoanti-
bodies after or undetectable autoantibodies before rituximab treatment
(Figure 1).Apossible explanation for nondecreasing antibodies could be
insufﬁcient eradication of antibody-producing plasma cells. Indeed,
long-lived plasma cells were detected in the spleen of ITP patients
nonresponsive to rituximab treatment and it has been suggested that
B-cell depletion promotes the differentiation and settlement of these
long-lived plasma cells in the spleen.15Although nonresponsive patients
without detectable platelet-associated autoantibodies ﬁt the ASH
criteria for ITP, these patients might represent a subgroup of ITP
patientswith possibly T-cell–mediated platelet destruction. Indeed,
Audia et al in this respect showed the importance of activated
splenic CD81 T cells in ITP patients unresponsive to rituximab.16
Furthermore, CD81 T cells were shown to contribute to the murine
splenocyte’s ability to induce thrombocytopenia; recently, Arthur et al
showed CD81 T-cell–mediated antibody-independent platelet clear-
ance in a murine model for refractoriness to platelet transfusions.17,18
Immune-suppressive treatment in combination with rituximab, as
recently published, may improve the limited response for rituximab as
single treatment.19 In this respect, itwill be interesting to study the effect
of combination therapy in ITP patients with and without detectable
platelet autoantibodies.
In conclusion, our results show absence of platelet-bound
antibodies to be associated with a low response to rituximab. Ad-
ditionally, response to rituximab appeared strongly associated with
a decline in platelet-bound antibodies. Our ﬁndings importantly
implicate that both antibody negativity vs strong antibody presence
might enable a more individualized therapeutic approach in this
group of ITP patients.
The online version of this article contains a data supplement.
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Figure 1. Direct PIFT results and platelet counts prior to
initiation with rituximab and at the time of the highest
platelet counts reached within 10 weeks after start of
rituximab treatment of 80 serially tested ITP patients. X-axis
for panel B also applies for panel A. (A) CR, n5 16; PR, n5 16;
MR, n 5 8; NR, n 5 40. Direct PIFT scores before (pre) and at
the time of the highest platelet count within 10 weeks after
(post) treatment with rituximab: 0, negative; 1, positive; 2, strong
positive; and 3, very strong positive. Changes in antibody
detection results are indicated by means of connecting lines. (B)
Platelet counts before and the highest platelet count within 10
weeks after treatment with rituximab.
Table 1. Platelet-associated antibody detection prior to initiation
with rituximab
P = .006
In the NR group, we found significantly (P 5 .006) more patients without
detectable autoantibodies than in the response group (CR 1 PR 1 MR).
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